Core Viewpoint - Chao Yun Group (06601) announced a strategic acquisition of 100% equity in Hebei Kangda Co., Ltd. for a maximum consideration of RMB 450 million (approximately HKD 495 million), aiming to enhance its market competitiveness in the home care product category in Northern China [1] Group 1 - The acquisition will allow the company to integrate the financial performance of the target company into its financial statements, thereby becoming an indirect wholly-owned subsidiary [1] - The target company has over 30 years of experience in the Northern China market and is a leading enterprise in home care products, which provides a strong customer resource base and promising growth prospects [1] - The strategic acquisition aims to optimize the company's industrial layout in the Northern region, enhancing its market coverage and depth in the domestic terminal market [1] Group 2 - The dual-brand synergy of "Chao Wei + Qiang Shou" will create complementary advantages, driving product innovation, technology research and development, and supply chain collaboration, thereby improving market competitiveness and operational efficiency [2] - The acquisition is expected to quickly increase market share in household insecticides and home cleaning categories, solidifying the company's leading position in the industry [2] - The target company's stable financial indicators will enhance the overall revenue scale and profitability of the group, creating sustainable long-term value for the company and its shareholders [2]

Core Viewpoint - Wei Jun Biotechnology (00660.HK) reported a revenue of approximately HKD 377 million for the fiscal year ending June 30, 2025, representing an increase of about 1.9% compared to the previous year. The company also improved its net loss to approximately HKD 14.6 million from HKD 44.2 million in the prior year, primarily due to a significant reduction in impairment losses on non-financial assets [1]. Financial Performance - The group's revenue and gross profit remained relatively stable compared to the previous year, with a reported revenue of approximately HKD 377 million [1]. - The net loss for the fiscal year ending June 30, 2025, was approximately HKD 14.6 million, a significant improvement from the net loss of approximately HKD 44.2 million for the fiscal year ending June 30, 2024 [1]. - The improvement in net loss was mainly attributed to a substantial decrease in impairment losses on non-financial assets during the reporting period [1]. Strategic Outlook - The company plans to continue pursuing strategic acquisitions to capture new business opportunities in the Chinese market, aiming to further strengthen its revenue and profit base [1]. - The company is actively seeking projects with growth potential for acquisition or investment and is in discussions with various parties regarding such opportunities [1].